Newtek商業服務 NEWT 深 滬
已收盤 08-01 16:00:00 美东时间
11.20
-0.240
-2.10%
華盛通- 最 高11.279
- 今 開11.22
- 成交量 41.56万股
- 最 低 11.07
- 昨 收 11.44
- 總市值 2.95亿
- 52周最高 14.92
- 市盈率 靜 5.73
- 換手率 1.58%
- 52周最低 8.74
- 委 比 76.13%
- 總股本 2634.20万
- 歷史最高 31.52
- 量 比 1.11
- 振 幅 1.83%
- 歷史最低 -16.382
- 每 手 1
- 風險率 1.10%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多NewtekOne amends revolving credit facility with Capital One
NewtekOne (NASDAQ:NEWT) announced on Tuesday the amendment of a revolving credit facility, which aims to fund the origination of alternative loan program loans before they are placed into securitizati...
07-29 21:14
Piper Sandler Maintains Neutral on NewtekOne, Raises Price Target to $12
Piper Sandler analyst Crispin Love maintains NewtekOne (NASDAQ:NEWT) with a Neutral and raises the price target from $11.5 to $12.
07-29 20:08
NewtekOne Affirms FY2025 GAAP EPS Guidance of $2.10-$2.50 vs $2.24 Est
NewtekOne (NASDAQ:NEWT) affirms FY2025 GAAP EPS guidance from $2.10-$2.50 to $2.10-$2.50 vs $2.24 analyst estimate..
07-29 04:18
NewtekOne Q2 EPS $0.52 Misses $0.53 Estimate, Sales $70.198M Miss $73.885M Estimate
NewtekOne (NASDAQ:NEWT) reported quarterly earnings of $0.52 per share which missed the analyst consensus estimate of $0.53 by 1.33 percent. This is a 20.93 percent increase over earnings of $0.43 per share from the same
07-29 04:01
苹果、微软、亚马逊、Meta财报来袭
作者丨Oliver Rodzianko 编译 | 华尔街大事件 本周科技巨头、能源巨头、金融公司、医疗保健行业领袖和消费者品牌将陆续发布大量财报。 焦点将集中...
07-28 20:40
Earnings Scheduled For July 28, 2025
Companies Reporting Before The Bell • Bank of Hawaii (NYSE:BOH) is likely to re...
07-28 16:32
A Glimpse of NewtekOne's Earnings Potential
NewtekOne (NASDAQ:NEWT) is gearing up to announce its quarterly earnings on Mon...
07-26 01:02
韩国市场开始狂飙：动辄单日翻倍，Upbit日交易量破百亿美元
转载来源：火讯财经 文章来源： Zen 作者：Zen，PANews 7月，沉寂的韩国虚拟资产市场正式复苏，迎来了一次“量价齐升”的爆发行情...
07-24 23:55
Keefe, Bruyette & Woods Maintains Market Perform on NewtekOne, Lowers Price Target to $12
Keefe, Bruyette & Woods analyst Timothy Switzer maintains NewtekOne (NASDAQ:NEWT) with a Market Perform and lowers the price target from $13 to $12.
07-11 23:49
Traws Pharma Seeks FDA Guidance On TXM For Bird Flu; Submits Phase 2 Studies For TXM, Ratutrelvir In Flu And COVID
Phase 2 protocol submitted to HREC to evaluate tivoxavir marboxil (TXM) in a combined seasonal and bird flu study in the Southern HemisphereBriefing documents submitted to FDA for a Type D meeting request to continue
06-30 18:45
